This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Patent Setback for J&J

A U.S. District Court judge upheld a 2005 verdict from a jury that had found in favor of Boston Scientific (BSX - Get Report) in a patent case against Johnson & Johnson (JNJ - Get Report).

Judge Sue Robinson issued a ruling denying J&J's motion to overturn the verdict. A Delaware jury determined last year that the Cypher stent, made by J&J's Cordis unit, infringed Boston's Ding patent. The jury also said the patent was valid.

The Ding patent covers claims for a two-layer drug coating on a stent, a wire-mesh tube used to prop open arteries that have been cleared of blockages.

Boston Scientific, a Massachusetts-based medical-device seller, will next have to contend with an appeal from Cordis.

The warring sides know each other well, and not just on the product competition and litigation fronts. Earlier this year, Boston Scientific outlasted New Jersey's J&J in a drawn-out bidding battle for Indianapolis-based defibrillator maker Guidant.

Judge Robinson's ruling was her third in the past six weeks regarding patent disputes between the two companies, J&J said. In the first decision, she agreed with a jury verdict from last year that Boston Scientific's Taxus stent and its Liberte and Express bare-metal stents infringed some Cordis' patents, one of which has now expired.

Another ruling saw the judge uphold the portion of a previous jury verdict that found the Cypher and the Cordis Bx Velocity stents infringed Boston Scientific's Jang patent. Cordis is appealing the judge's decisions on the Jang and Ding patents to a federal appeals court in Washington.

Shares of Boston Scientific were up 54 cents, or 2.8%, to $20.06. J&J was adding 8 cents at $61.55.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BSX $18.26 1.50%
JNJ $101.16 0.03%
AAPL $131.78 -0.20%
FB $80.14 -0.50%
GOOG $539.78 -0.00%

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs